Browsing: Morgan

Salesforce (NYSE:CRM – Get Free Report) had its price objective upped by equities research analysts at Morgan Stanley from $185.00 to $235.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the CRM provider’s stock. Morgan Stanley’s price objective would suggest a potential downside of 0.02%…

Aug. 18, 2026 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the appointment of Bruce N. Rogers, Ph.D., as Venture Partner. Dr. Rogers will leverage his extensive background in medicinal chemistry, translational science, neuroscience, and immunology to develop and scale…